

### Hippocampal volume reduction specific for later transition to psychosis or substance-associated effects?

We read with great interest the article by Witthaus and colleagues<sup>1</sup> recently published in the *Journal of Psychiatry and Neuroscience*. The authors found that, compared with controls, patients at ultra-high risk (UHR) had significantly smaller volumes of the hippocampus corpus and tail bilaterally. The UHR patients who later developed psychosis had smaller right hippocampus corpus and tail volumes than did those who did not develop psychosis. The authors concluded that the hippocampal volume reduction may be indicative of the prodromal phase of schizophrenia and may represent a risk factor for transition into psychosis.

However, significantly reduced (right) hippocampal volumes in UHR patients with later transition are in contrast to previous region-of-interest studies. We and others<sup>2,3</sup> showed no volumetric hippocampal differences between converters and nonconverters, suggesting that hippocampal volumes are not related to an at-risk mental state with later transition to psychosis. Instead, there is evidence for hippocampal and parahippocampal volume reductions developing as the disease progresses, at least during the first psychotic episode.<sup>4,5</sup>

These inconsistent results may be attributable to different ascertainment strategies, transition criteria, clinical follow-up periods, cannabis abuse and medication effects.<sup>6</sup> Witthaus and colleagues<sup>1</sup> reported that within 9 months after magnetic resonance imaging, 2 UHR patients made the transition to psychosis, and 6 patients were lost to clinical follow-up and therefore considered to be converters (assumption based on available clinical information). In contrast to our and other previous neuroimaging studies, patients at high risk of psychosis were followed-up for at least 1 year, and standardized criteria<sup>7</sup> were applied to de-

termine if any patients made the transition to psychosis.

In addition, Witthaus and colleagues<sup>1</sup> did not report complete information on the medication status of the UHR patients. They stated that 11 of 29 patients had received atypical antipsychotics, alluding to short-term risperidone or olanzapine treatment. However, it is unclear whether those at UHR who later transitioned to psychosis received more or less antipsychotics compared with UHR patients who did not transition.

This raises the question as to whether the volumetric alterations seen in the UHR group could be an effect of antipsychotic medication. We agree with the authors that the results of the study cannot simply be explained by an effect of antipsychotic medication taken only for an average of 1.9 days. However, 2 recently published systematic reviews on the effects of antipsychotics on the brain concluded that antipsychotics may contribute to brain structural changes observed in psychosis and that their effects are regional rather than global.<sup>8,9</sup>

Moreover, UHR individuals with cannabis abuse were included if their psychotic symptoms began before the onset of cannabis abuse. However, recently published studies have shown an intrinsic influence of cannabis on brain structure and function.<sup>10,11</sup> There is evidence that the degree of acute psychotic symptoms following tetrahydrocannabinol administration modulated mediotemporal function among healthy men.<sup>11</sup> Furthermore, continuous cannabis use over 5 years led to progressive loss of brain volume among first-episode schizophrenia patients.<sup>10</sup>

Therefore, it would have been interesting to perform a statistical analysis covarying for effects of cannabis use or to compare hippocampal volumes in UHR patients with and without cannabis abuse. This could address the putative effect of cannabinoids on the hippocampus.

Despite the fact that neuroimaging studies have provided evidence that,

independent of psychotropic substances, there are detectable anatomic abnormalities at the level of total and regional brain volumes, the effects of cannabis and antipsychotics on hippocampal volume remain elusive. Until we have reliable UHR studies addressing the longitudinal effects of psychotropic substances on brain structures as the hippocampus, we must keep the potential impact of substance-associated effects in mind.

**Stefan Borgwardt, MD, PhD**  
**Renata Smieskova, MD**  
**Kerstin Bendfeldt, PhD**  
**Eva Bühlmann, MD**  
**Gregor Berger, MD**  
**Jacqueline Aston, MD**  
**Ute Gschwandtner, MD, PhD**  
**Marlon Pflueger, PhD**  
**Rolf-Dieter Stieglitz, PhD**  
**Anita Riecher-Rössler, MD, PhD**  
*Psychiatric Outpatient Department*  
*Psychiatric University Hospital*  
**Ernst-Wilhelm Radue, MD, PhD**  
*Medical Image Analysis Center*  
*University Hospital Basel*  
*Basel, Switzerland*

**Competing interests:** Dr. Borgwardt's research was supported by a personal grant from the Swiss National Science Foundation (PBB5B-106936). The sponsor had no role in the intellectual work, writing of this letter, or the decision to submit this letter for publication. Dr. Berger has received speaker honoraria from AstraZeneca, Lilly, and Janssen-Cilag. None declared for all other authors.

**Contributors:** All authors contributed to and have approved this letter.

### References

1. Witthaus H, Mendes U, Brune M, et al. Hippocampal subdivision and amygdalar volumes in patients in an at-risk mental state for schizophrenia. *J Psychiatry Neurosci* 2010;35:33-40.
2. Buehlmann E, Berger GE, Aston J, et al. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. *J Psychiatr Res*. Epub 2009 Nov. 24 ahead of print.
3. Velakoulis D, Wood SJ, Wong MT, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode

- psychosis, and ultra-high-risk individuals. *Arch Gen Psychiatry* 2006;63:139-49.
4. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. *Lancet* 2003;361:281-8.
  5. Job DE, Whalley HC, Johnstone EC, et al. Grey matter changes over time in high risk subjects developing schizophrenia. *Neuroimage* 2005;25:1023-30.
  6. Smieskova R, Fusar-Poli P, Allen P, et al. Neuroimaging predictors of transition to psychosis — a systematic review and meta-analysis. *Neurosci Biobehav Rev*. Epub 2010 Feb. 6 ahead of print.
  7. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. *Schizophr Res* 2003;60:21-32.
  8. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. *Psychol Med* 2009;39:1763-77.
  9. Smieskova R, Fusar-Poli P, Allen P, et al. The effects of antipsychotics on the brain: What have we learnt from structural neuroimaging of schizophrenia? A systematic review. *Curr Pharm Des* 2009; 15:2535-49.
  10. Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. *Am J Psychiatry* 2008; 165:490-6.
  11. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by delta9-tetrahydrocannabinol: a neural basis for the effects of cannabis sativa on learning and psychosis. *Arch Gen Psychiatry* 2009;66:442-51.

### Hippocampal alterations in ultra-high risk patients are independent from medication and cannabis use

In their comment on our article entitled "Hippocampal subdivision and amygdalar volumes in patients in an at-risk mental state for schizophrenia,"<sup>1</sup> Borgwardt and colleagues raise some critical

questions regarding our finding that hippocampal volume loss is related to an at-risk mental state. Instead, they argue that smaller right hippocampus corpus and tail volumes in ultra-high risk patients (UHR) who later developed schizophrenia compared with those who did not develop schizophrenia may be attributable to cannabis abuse and/or medication effects.

In fact, in our sample, one patient who transitioned into psychosis was taking antipsychotic medication and 7 who transitioned had never taken an antipsychotic. In comparison, in the UHR group that did not transition, 10 were taking antipsychotic medication and 11 were not. Notably, there was no significant difference in right hippocampal corpus and tail volume between these 4 groups ( $F_{3,27} = 0.668, p = 0.58$ ).

Among the UHR patients who transitioned into psychosis, only 1 had previous cannabis abuse (see the 3-month criterion we used<sup>1</sup>), whereas 7 did not use cannabis. Among the UHR patients who did transition, 8 had comorbid cannabis abuse and 13 were free of cannabis abuse. Again, when we compared the volumes of the right hippocampal corpus and tail, we found no significant difference between the groups ( $F_{3,27} = 1.146, p = 0.35$ ).

These findings suggest that the differences in the volume of the hippocampus corpus and tail between UHR patients who transitioned into psychosis and those who did not could not be accounted for by the effect of antipsychotic medication or cannabis abuse. Although 2 previous studies did not reveal hippocampal volume differences between converters and nonconverters,<sup>2,3</sup> we believe

that it would be premature to rule out anatomic abnormalities in UHR states in these brain regions. Our study indicates that hippocampal volume reduction may precede the onset of schizophrenia and may be present in prodromal stages, independent of medication effects or the presence or absence of cannabis abuse.

**Henning Witthaus, MD**  
**Martin Brüne, MD, PhD**  
**Georg Juckel, MD, PhD**  
*Department of Psychiatry*  
*Ruhr University Bochum*  
*LWL University Hospital*  
*Bochum, Germany*

**Competing interests:** None declared for Drs. Witthaus or Brüne. Dr. Juckel has received consultancy fees from Janssen-Cilag, AstraZeneca and Eli Lilly. He has received speakers fees and/or educational grants from Janssen-Cilag, AstraZeneca and Eli Lilly, Wyeth and Pfizer.

**Contributors:** All authors contributed to and have approved this letter.

### References

1. Witthaus H, Mendes U, Brüne M, et al. Hippocampal subdivision and amygdalar volumes in patients in an at-risk mental state for schizophrenia. *J Psychiatry Neurosci* 2010;35:33-40.
2. Buehlmann E, Berger GE, Aston J, et al. Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study. *J Psychiatr Res* 2009. Epub 2009 Nov. 24 ahead of print.
3. Velakoulis D, Wood SJ, Wong MT, et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra high-risk individuals. *Arch Gen Psychiatry* 2006;63: 139-49.